Puma Biotechnology, Inc.
59
9
12
37
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.9%
7 terminated/withdrawn out of 59 trials
84.1%
-2.4% vs industry average
3%
2 trials in Phase 3/4
76%
28 of 37 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (59)
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Role: collaborator
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Role: collaborator
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Role: collaborator
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Role: lead
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Role: lead
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Role: collaborator
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Role: collaborator
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Role: collaborator
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Role: lead
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Role: collaborator
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Role: collaborator
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Role: collaborator
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
Role: collaborator
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Role: collaborator
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
Role: collaborator
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
Role: collaborator
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Role: collaborator
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Role: lead
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Role: collaborator
Fulvestrant + Neratinib In Breast Cancer
Role: collaborator